preloader icon



Goldman Sachs Says These 2 Healthcare Stocks Have up to 130% Upside Potential

For investors seeking a solid return, few stock segments offer a better mix of risk, reward, and opportunity than healthcare stocks. While these stocks are known for their notoriously long product lead times and high overhead costs, they are also known for their ability to turn sharply on a new catalyst and generate strong returns. That dynamic is part and parcel of the biopharmaceutical research field. The biotech companies spend their capital and efforts – huge amounts of each – on the discove
Click Here To Get Funded!